AzTrials
AzTrials

Postoperative Pain ManagementDexBupiVsBupiNCT07388251

Effect of Intraperitoneal Dexmedetomidine Added to Bupivacaine 0.25% Versus Bupivacaine Alone on Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy

A study testing Bupivacaine 0.25% intraperitoneal and Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitoneal in people with Postoperative Pain Management and Cholelithiasis, run by Ain Shams University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Laparoscopic cholecystectomy (LC) is the preferred surgical technique for the management of cholelithiasis owing to its advantages over open surgery, including reduced postoperative pain, shorter hospital stay, and faster recovery. Read more about this study

Who is it for?
Ages 18 to 60 years
What is being tested?
Bupivacaine 0.25% intraperitoneal and Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitoneal
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteEgypt
Study dates
2 Mar 2025to 21 Sep 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Patients scheduled for laparoscopic cholecystectomy.
  • ASA I and II.
  • Agreement to participate in the study by the participant or his local guardian.

Who cannot join

  • BMI less than 18 or > 30 kg/m2.
  • Psychiatric illness.
  • Coagulation disorders.
  • Those allergic to local anesthetics, or dexmedetomidine.
  • Patients with heart block or heart rate less than 50 bpm.
  • Intraoperatively, patients who will be converted into open cholecystectomy.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • intensive care unit Department, Ain Shams University Hospital

    Cairo, Cairo Governorate, 11517

Other trials in Egypt

About this study

Official title: Comparative Study of the Effect of Intraperitoneal Instillation of Dexmedetomidine Combined With Bupivacaine 0.25% Versus Bupivacaine 0.25% Alone in Patients Undergoing Laparoscopic Cholecystectomy

Laparoscopic cholecystectomy (LC) is the preferred surgical technique for the management of cholelithiasis owing to its advantages over open surgery, including reduced postoperative pain, shorter hospital stay, and faster recovery. Nevertheless, postoperative pain-particularly in the early postoperative period-remains a clinical challenge and may lead to increased analgesic requirements, delayed ambulation, and prolonged hospitalization. Postoperative pain after LC is multifactorial, resulting from peritoneal irritation, pneumoperitoneum-induced diaphragmatic stretching, and residual intraperitoneal carbon dioxide.

Intraperitoneal instillation of local anesthetics has been widely incorporated into multimodal analgesic strategies to reduce postoperative pain and opioid consumption after laparoscopic surgery. Bupivacaine is commonly used for this purpose; however, its limited duration of action has prompted the use of adjuvants to enhance analgesic efficacy. Dexmedetomidine, a selective α2-adrenergic agonist, possesses analgesic, sedative, and opioid-sparing properties with minimal respiratory depression, making it a promising adjunct to local anesthetics.

Read more

This randomized, double-blinded clinical trial was conducted at Ain Shams University Hospitals to compare the analgesic efficacy and safety of intraperitoneal dexmedetomidine combined with bupivacaine versus bupivacaine alone in patients undergoing elective laparoscopic cholecystectomy. Thirty adult patients with ASA physical status I-II were randomly allocated into two equal groups. Group A received intraperitoneal bupivacaine 0.25%, while Group B received intraperitoneal bupivacaine 0.25% combined with dexmedetomidine 0.5 µg/kg, instilled over the gallbladder bed at the end of surgery.

The primary outcome was postoperative pain intensity assessed using the Visual Analog Scale (VAS) over the first 24 hours. Secondary outcomes included hemodynamic parameters, oxygen saturation, time to first rescue analgesia, total opioid consumption, and incidence of postoperative adverse events.

The addition of dexmedetomidine to intraperitoneal bupivacaine significantly reduced postoperative pain scores during the early postoperative period, prolonged the time to first rescue analgesia, and markedly decreased opioid consumption without compromising respiratory function. Hemodynamic changes were mild and clinically acceptable, and adverse events were comparable between groups.

In conclusion, intraperitoneal dexmedetomidine combined with bupivacaine provides superior postoperative analgesia and an opioid-sparing effect compared with bupivacaine alone following laparoscopic cholecystectomy, with an acceptable safety profile.

Read the detailed description

This study was designed as a prospective, randomized, double-blinded clinical trial conducted at Ain Shams University Hospitals, Cairo, Egypt, over a six-month period. The trial aimed to evaluate the perioperative effects of intraperitoneal instillation of local anesthetic solutions with or without an adjuvant in patients undergoing elective laparoscopic cholecystectomy, under standardized anesthetic and surgical conditions. All enrolled patients underwent laparoscopic cholecystectomy performed by the same surgical team using a standardized four-port technique to minimize variability in surgical manipulation and operative time. Pneumoperitoneum was established using carbon dioxide insufflation and maintained at a constant intra-abdominal pressure throughout the procedure. Preoperative preparation included patient education regarding postoperative pain assessment using the 10-point Visual Analog Scale (VAS) one day before surgery. Patients received standardized premedication with oral alprazolam 0.25 mg on the evening before surgery and on the morning of surgery. In the operating room, a peripheral intravenous line was secured using an 18-gauge cannula, and standard monitoring was applied, including five-lead electrocardiography, non-invasive blood pressure measurement, pulse oximetry, and heart rate monitoring. General anesthesia was induced using intravenous fentanyl (2 μg/kg) and propofol until loss of verbal response. Neuromuscular blockade was achieved using atracurium (0.5 mg/kg) to facilitate tracheal intubation. Anesthesia was maintained with sevoflurane in a mixture of oxygen and nitrous oxide, targeting a minimum alveolar concentration of approximately 1.3. Additional doses of atracurium were administered as required, guided by train-of-four monitoring. All patients received standardized intraoperative analgesic and antiemetic prophylaxis. This included intravenous administration of diclofenac 75 mg diluted in 100 mL of normal saline, paracetamol 1 g, ondansetron 4 mg, and dexamethasone 0.1 mg/kg. Local anesthetic infiltration at trocar insertion sites was performed before skin incision. At the completion of the surgical procedure, following gallbladder removal and peritoneal lavage, intraperitoneal instillation of the study solution was performed through the laparoscopic instillation port, with uniform distribution over the gallbladder bed. The study solution was prepared by an anesthesiologist not involved in patient management or postoperative assessment to ensure blinding. The operating surgeon, patients, and investigators responsible for postoperative data collection were unaware of the contents of the instilled solution. At the end of surgery, residual neuromuscular blockade was reversed using neostigmine (0.05 mg/kg) in combination with glycopyrrolate (0.01 mg/kg). Tracheal extubation was performed once standard extubation criteria were met, and patients were transferred to the post-anesthesia care unit (PACU) for routine monitoring. Postoperative management followed a standardized protocol for all patients. Hemodynamic parameters and oxygen saturation were monitored at predefined intervals during the postoperative period. Pain assessment was conducted using the Visual Analog Scale at regular intervals during the first 24 hours following surgery. Rescue analgesia was administered according to a predefined institutional protocol when clinically indicated. Randomization was performed using a computer-generated random sequence, and allocation concealment was ensured through sealed opaque envelopes prepared by an independent investigator. The study maintained double blinding throughout data collection and analysis phases. Data collection was conducted using standardized case report forms. All collected data were anonymized prior to analysis to maintain patient confidentiality. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) software, version 23. Continuous variables were summarized using appropriate descriptive statistics, and comparative analyses were conducted using standard parametric or non-parametric tests as applicable. A two-sided p-value of less than 0.05 was considered statistically significant. Ethical approval for the study was obtained from the Ethical Committee of the Faculty of Medicine, Ain Shams University. Written informed consent was obtained from all participants prior to enrollment, in accordance with the Declaration of Helsinki and institutional guidelines.

Being tested
Bupivacaine 0.25% intraperitoneal, Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitoneal
Medical subject headings
Cholelithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacaine 0.25% intraperitonealDrug

    Patients receive 20 mL of 0.25% bupivacaine instilled intraperitoneally across the gallbladder bed at the end of laparoscopic cholecystectomy. Standard anesthesia and perioperative care are maintained for all participants.

  • Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitonealDrug

    Patients receive 20 mL of 0.25% bupivacaine combined with 0.5 µg/kg dexmedetomidine instilled intraperitoneally across the gallbladder bed at the end of laparoscopic cholecystectomy. Standard anesthesia and perioperative care are maintained.

Study groups in NCT07388251
Study groupRoleWhat they receive
Bupivacaine 0.25% intraperitoneal instillationActive comparatorPatients undergo laparoscopic cholecystectomy and receive intraperitoneal bupivacaine alone. Postoperative pain, hemodynamics, and analgesic requirements are monitored to evaluate standard pain control.
Receives: Drug: Bupivacaine 0.25% intraperitoneal
Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitoneal instillationExperimentalPatients undergo laparoscopic cholecystectomy and receive intraperitoneal bupivacaine combined with dexmedetomidine. Postoperative pain, hemodynamics, and analgesic requirements are monitored to assess the added analgesic effect of dexmedetomidine.
Receives: Drug: Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitoneal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative pain intensity measured by Visual Analog Scale (VAS)

    Pain intensity will be assessed using the 10-point Visual Analog Scale (VAS) at multiple time points: At the entry to the PACU, and at 1, 2, 4, 6, 8, 16, and 24 hours postoperatively. VAS scoring: 0 = no pain, 2-4 = mild pain, 4-6 = moderate pain, 6-8 = severe pain, 8-10 = worst pain imaginable. The mean VAS score during the first 24 postoperative hours will serve as the primary outcome to evaluate analgesic efficacy between study groups.

    Measured: From the entry to the PACU up to 24 hours postoperatively

Secondary outcomes (6)
  1. Mean arterial blood pressure

    Mean arterial blood pressure (MAP), measured in mmHg, Measurements will be obtained immediately after intraperitoneal instillation of local anesthetics, at the end of surgery, on admission to the post-anesthesia care unit (PACU), and at 1, 2, 4, 6, 8, 16, and 24 hours postoperatively.

    Measured: From the intraperitoneal instillation of local anesthetics and up to 24 hours postoperatively

  2. Heart rate

    Heart Rate (HR), measured in (Beat/minute). Measurements will be obtained immediately after intraperitoneal instillation of local anesthetics, at the end of surgery, on admission to the post-anesthesia care unit (PACU), and at 1, 2, 4, 6, 8, 16, and 24 hours postoperatively.

    Measured: From the intraperitoneal instillation of local anesthetics and up to 24 hours postoperatively

  3. Peripheral Oxygen Saturation (SpO₂)

    Peripheral Oxygen Saturation (SpO₂), measured in (%). Measurements will be obtained after intraperitoneal instillation of local anesthetics, at the end of surgery, on admission to the post-anesthesia care unit (PACU), and at 1, 2, 4, 6, 8, 16, and 24 hours postoperatively.

    Measured: From the intraperitoneal instillation of local anesthetics and up to 24 hours postoperatively

  4. Time to first rescue analgesia

    The duration in minutes from the end of surgery to the administration of the first rescue analgesic (pethidine 50 mg) will be recorded.

    Measured: From the end of surgery to the administration of the first rescue analgesic.

  5. Total pethidine consumption after surgery

    The total amount of pethidine (mg) administered to each patient as rescue analgesia during the first 24 hours postoperatively will be recorded. This outcome evaluates the overall analgesic requirement and opioid-sparing effect of the intraperitoneal interventions.

    Measured: Within the first 24 hours postoperatively

  6. Adverse events

    Nausea, Vomiting, Pruritis and Pain

    Measured: Within the first 24 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2026
  2. Study start2 Mar 2025
  3. Primary completion1 Sep 2025
  4. Study completion21 Sep 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a prospective, randomized, double-blinded, parallel-group interventional study. Adult patients undergoing elective laparoscopic cholecystectomy are randomly assigned to receive intraperitoneal instillation of a local anesthetic solution with or without an adjuvant. Allocation is concealed using sealed opaque envelopes, and both patients and postoperative assessors are blinded. All participants undergo standardized anesthetic and surgical procedures. Postoperative assessments, including hemodynamic monitoring and pain evaluation using the Visual Analog Scale, are performed at predefined intervals to assess the effects of the intervention. The study evaluates the analgesic efficacy and safety of the tested solutions while maintaining consistent perioperative care.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07388251
Sponsor's protocol ID
FMASU MS 180/ 2025
Acronym
DexBupiVsBupi
Status last verified
Mar 2025
First submitted
17 Dec 2025
Last updated
5 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (IPD) including age, weight, ASA status, FLACC scores, and analgesic consumption will be shared with qualified researchers upon request after publication. Requests will be reviewed by the Principal Investigator, and approved data will be shared via a secure repository. No personal identifiers will be included

Questions about this trial

What is this clinical trial studying?

A study testing Bupivacaine 0.25% intraperitoneal and Bupivacaine 0.25% + Dexmedetomidine 0.5 µg/kg intraperitoneal in people with Postoperative Pain Management and Cholelithiasis, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative pain intensity measured by Visual Analog Scale (VAS) (time frame: From the entry to the PACU up to 24 hours postoperatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in